线粒体靶向抗肿瘤药物的生物活性研究

Studies on the Bioactivity of Mitochondria-targeted Antitumor Drugs

在社会快速发展的影响下,人们对肿瘤的了解在不断的研究探索中越来越深入,并发现在肿瘤发生发展中,线粒体功能随着肿瘤的发生、发展也相应的发生着改变。线粒体是细胞死亡的关键调控因素,故线粒体靶向药物成为了抗肿瘤药物研发的重要方向,尤其是针对其靶向治疗药物更成为了抗肿瘤治疗的新课题。文章主要对当前抗肿瘤新型靶向治疗药物—线粒体靶向抗肿瘤药物进行研究,对其与离体线粒体、脱氧核糖核酸(DNA)、人血清白蛋白(HSA)的相互作用及监测方法进行总结,旨在对线粒体靶向抗肿瘤药物的生物活性进行了解。

With the rapid development of society and the unceasing appetite for exploration, people＇s understanding of the tumor has become more and more deeply. Mitochondrial function can change with the occurrence, development and treatment of the tumor. Mitochondria play a crucial role in regulating cell growth and survival pathways. Therefore, improvement of the targeting ability of antitumor drugs to mitochondria will increase the treatment efficacy for tumor. In this paper, in order to provide a reference for the popularization and application of mitochondria-targeted antitumor drugs, their bioactivity was studied. The monitoring methods and the interactions between mitochondria-targeted antitumor drugs and isolated mitochondria, deoxyribonucleic acid （DNA）, human serum albumin （HSA） were summarized.